MeCRU Research Unit officially launched as the Paediatric COVID-19 VACCINE Trial Site
Mecru Clinical Research Unit (MeCRU), at SMU has been officially launched as the research site for Phase III Paediatric COVID-19 Vaccine study conducted by the Numolux Group and Sinovac on 10 September 2021. The very first child and the second one had the honour to receive their jabs which kick started the study.
In a hybrid ceremony of face to face and virtual sessions, messages of support and congratulations came as far as China and from a representative of the department of health on behalf of Dr Joe Phaahla, the Minister of Health. Prof Peter Mbati, the Vice-Chancellor also congratulated MeCRU for being identified as a site and wished everyone success in this noble campaign to stem the de of the pandemic amongst young people.
The study is a multi-centre, randomized, double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of SINOVAC Inactivated COVID-19 Vaccine
(CoronaVac®) in children and adolescents aged 6 months to 17 years.
See download for more on this Newsletter Edition